| Ceritinib | None | ||
| 150MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| ZYKADIA is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. | |||
|
Yes
| |||
| Zykadia | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||||
| *, *-****************** ****** ** *** ********* ** ********** ********, ************ *** ****** ****** ********* | *,*-** (***********) *********** ****** ** *** ********* ** ********** ********, ************ *** ****** ****** ********* | *,*,*,*-**********-**-********* *********** ** ***** ******** *********** | ********* *** ************ ** ******* ****** ********** | ********* *** ************ ** ******* ****** ********** | ********* *** ************ ** ******* ****** ********** | ******* ** ***** *** ********** | *********** ***** ** *-******-**-(*-**********-*-******-*-*********-*-**-******)-**-[*-(*******-*-********)-******]-**********-*, *-******* | ********** ********* | *,*-***************** ********* *** ***** **** | *,*-***************** ********* *** ***** **** | *,*-***************** ********* *** ***** **** | *,*-***************** ********* *** ***** **** |
| Ceritinib | None | ||
| 150MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| ZYKADIA is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. | |||
|
Yes
| |||
| Zykadia | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||||
| *, *-****************** ****** ** *** ********* ** ********** ********, ************ *** ****** ****** ********* | *,*-** (***********) *********** ****** ** *** ********* ** ********** ********, ************ *** ****** ****** ********* | ********* *** ************ ** ******* ****** ********** | ********* *** ************ ** ******* ****** ********** | ********* *** ************ ** ******* ****** ********** | ******* ** ***** *** ********** | *********** ***** ** *-******-**-(*-**********-*-******-*-*********-*-**-******)-**-[*-(*******-*-********)-******]-**********-*, *-******* | ********* *********** | ********** ********* | *,*-***************** ********* *** ***** **** | *,*-***************** ********* *** ***** **** | *,*-***************** ********* *** ***** **** | *,*-***************** ********* *** ***** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|